GSK Reports Q2 Results and Growth Agenda
GSK plc announced its second-quarter financial results and an update on its 'Accelerate Growth' strategy. The company reported a 5% increase in sales and a 7% rise in core operating profit.
GSK plc has reported its second-quarter 2026 results, with sales increasing by 5% to £8.4 billion and core operating profit rising by 7% to £2.8 billion.
The company also provided an update on its 'Accelerate Growth' agenda, focusing on late-stage research and development across oncology, respiratory diseases, hepatitis, vaccines, and HIV. Key sales drivers in the second quarter were Specialty Medicines and Vaccines.
Specialty Medicines sales grew by 14% to £3.8 billion, with contributions from products including Arexvy, Nucala, Cabenuva, Dovato, Jemperli, Benlysta, Ojjaara, and Apretude. The Vaccines portfolio saw an 8% increase in sales, reaching £2.3 billion, supported by Shingrix and other vaccine products.
The pharmaceutical company reaffirmed its financial guidance for 2026, expecting sales and operating profit to be at the upper half of the range and earnings per share at the lower half. GSK continues to focus on R&D for new medicines and vaccines.